Luminary Group’s Post

🌟 I'm thrilled to congratulate my friends, mentors, and former teammates at Formation Bio on a tremendously successful fundraise! 🌟 "Bring new treatments to patients faster and more efficiently" is an incredibly important mission. It also represents an incredibly long and difficult journey—one that I know Benjamine Liu would emphasize the team is just getting started on, despite how far we've already come! What does one fundraise mean for such a journey? It means well-deserved confidence in the team and its culture to realize the mission. It means realistic optimism for the vision of a world where every disease has a treatment. It means excitement in the potential for innovation at the intersection of AI, tech, and pharma. It means conviction to champion the mission. It's also a recognition of Ben's vision and unwavering resolve -- virtues that influenced me tremendously, as I know they have every Spark. I am immensely proud of this team, and excited to see more and more positive impact on the world through their journey. I'm beyond grateful for the portion of that journey I was able to make with them, and for the personal growth and learning imparted. Here's to the journey ahead, bringing new treatments to patients faster and more efficiently 🚀💡 #Innovation #Healthcare #Funding #AI #Tech #Pharma #ProudMoment

In exploring a potential R&D partnership, sharing non-confidential data is usually the first step. But what data do you share to pique interest? How do you ensure you don’t compromise your IP position? And how can innovators present their data in an appealing way?   Join the #jnjinnovation #JLABS program for insights on best practices and watchouts.   #lifesciences #startups and innovators are invited to register for the program here: https://jji.jnj/3Kw2OlG  

#Partnerships with external investors like Tesi are crucial for BC Platforms' growth and internationalization. 🚀 #data #drugdevelopment #healthcare #precisionmedicine #healthtech #healthtechinnovation

“What Does J&J Look For When Evaluating an Early Startup?” Learn how Johnson & Johnson leverages its extensive breadth and scale to positively impact lives through its Research & Development endeavors in Med Tech and Pharmaceuticals. Dr. William Hait discusses the company's operational models and highlights the journey of a product from conceptualization to market deployment. View the full video on our YouTube here ⬇️: https://lnkd.in/eFniGDUE #NYUStern #FubonCenter #Fintech #JohnsonandJohnson #Medtech

Thoughts on this? >> Digital health funding flattens out, PitchBook report shows >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #biotech #productmarketing #pharmaceutical #healthcare #pharma

ClavystBio CEO Khoo Shih sat down with Citeline Commercial Scrip’s Mandy Jackson to discuss the growing traction in the biotech market. Financing is showing signs of improvement, driven by increased M&A activity from big pharma acquiring smaller firms at attractive valuations. IPOs for clinical-stage companies are also on the rise. Khoo Shih highlighted that while financing prospects are improving, success hinges on companies with a well-articulated story and clear milestones: Key takeaways: • Clarity in Milestones: This is a pivotal time for biotechs to sharpen strategies and communicate their milestones. Investors are looking for companies that can articulate a clear path to value-creating clinical milestones. • Platform Potential: While platforms are valued, the real focus is on the progression of drug candidates. • Strong Insider Commitment: Demonstrating robust internal support is crucial. Read the full article here (for subscribers only): https://lnkd.in/g7DZjZwz

Could this be of interest to you? In exploring a potential R&D partnership, sharing non-confidential data is usually the first step. But what data do you share to pique interest? How do you ensure you don’t compromise your IP position? And how can innovators present their data in an appealing way?   Join the #jnjinnovation #JLABS program for insights on best practices and watchouts.   #lifesciences #startups and innovators are invited to register for the program here: https://jji.jnj/3Kw2OlG

In exploring a potential R&D partnership, sharing non-confidential data is usually the first step. But what data do you share to pique interest? How do you ensure you don’t compromise your IP position? And how can innovators present their data in an appealing way?   Join the #jnjinnovation #JLABS program for insights on best practices and watchouts.   #lifesciences #startups and innovators are invited to register for the program here: https://jji.jnj/3KuU5jG

John Carroll and Chris Dokomajilar present a cautious optimism in the Endpoints News article for the life sciences / biotech sector this year, emphasizing a potential rebound in mergers and acquisitions (M&A), initial public offerings (IPOs), and venture funding. Following a slump, there's a significant uptick in M&A activity in Q4 2023, driven by Big Pharma's strategic acquisitions to fill pipeline gaps, suggesting a trend towards smaller, strategic deals continuing into 2024. IPO activity is hinted at possibly regaining momentum, with examples of successful early IPOs inspiring confidence,e.g., CG Oncology. Venture funding, however, faced a tough period, with investments cratering but showing signs of stabilization and potential recovery as investors adjust to a post-boom environment, looking towards M&A and IPOs for liquidity and growth opportunities. Hoping for rate cuts by the Fed. Yesterday did not help. Hopefully, March will be a different outcome. But more likely May/ June. Buckle up! #biotechnology #venturecapital #mergersandacquisitions

Thoughts on this? >> Digital health funding flattens out, PitchBook report shows >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #biotech #productmarketing #pharmaceutical #healthcare #pharma